Mad Money's Jim Cramer says call your broker and get a piece of Shake Shack's IPO. The deal is practically engineered to have big pop out of the gate, he says.» Read More
CNBC's Jim Cramer explains why he is watching earnings momentum in utility names.
Jim Cramer explains why he is taking a long-term view of Merck, and if Novo Nordisk will break through.
Small capitalization stocks are primed for a 'January Effect' tailwind that may help them post big gains versus their large cap peers next year.
From retail to restaurants, "Mad Money" host Jim Cramer is naming his top buys in the wake of the Dow hitting 18K.
Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.
From retail to restaurants, Mad Money host Jim Cramer is naming his top buys in the wake of the Dow hitting 18k.
As the U.S. reduces its military budget, Jim Cramer sees allied countries are arming themselves. This is good news for one group of stocks.
Mad Money host Jim Cramer weighs in on decline in biotech stocks after Express Scripts announced it will exclusively cover AbbVie's approved hepatitis C drug.
Mad Money host Jim Cramer explains the best trades now that the Dow has jumped over the 18,000 hurdle, and positive GDP data. Cramer also says he thinks the oil ETF USO does look like it's trying to bottom.
The biotech sector has made a drastic change in the past few days. Jim Cramer goes off the charts to find out if they could be headed down further.
With such awesome GDP data announced Tuesday, Cramer gives the inside scoop on which stocks fund managers will be buying as a result.
The "Fast Money" traders share their final trades of the day.
Express Scripts will exclusively cover AbbVie's newly approved hepatitis C drug. Insight on the moves in biotech stocks, with CNBC's Meg Tirrell.
The Fast Money traders take a look at today's biggest market movers.
Pacific Crest said the Surface Pro 3 is surprisingly strong, and the stock rallied on the news.
The "Fast Money" traders discuss news Keurig is recalling nearly 7 million coffee makers.
Michael Pachter, Wedbush Securities, explains why he thinks the GoPro Hero is the "gift of choice" this holiday season.
Alibaba has sat out of the market rally. Mark Mahaney, RBC Capital Markets analyst, shares his prediction for the stock.
"Fast Money" trader Steve Grasso dissects the key moves in the iShares Russell 2000 ETF, the IWM.
Dissecting the Dow's climb to 18,000, and whether it matters, with the "Fast Money" traders.